Performance of amplicon and capture based next-generation sequencing approaches for the epidemiological surveillance of Omicron SARS-CoV-2 and other variants of concern
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0289188 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Carlos Daviña-Núñez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Centre for Disease Prevention and Control, Axencia Galega de Innovación, Servicio Gallego de Salud.
Abstract (Originalsprache)
To control the SARS-CoV-2 pandemic, healthcare systems have focused on ramping up their capacity for epidemiological surveillance through viral whole genome sequencing. In this paper, we tested the performance of two protocols of SARS-CoV-2 nucleic acid enrichment, an amplicon enrichment using different versions of the ARTIC primer panel and a hybrid-capture method using KAPA RNA Hypercap. We focused on the challenge of the Omicron variant sequencing, the advantages of automated library preparation and the influence of the bioinformatic analysis in the final consensus sequence. All 94 samples were sequenced using Illumina iSeq 100 and analysed with two bioinformatic pipelines: a custom-made pipeline and an Illumina-owned pipeline. We were unsuccessful in sequencing six samples using the capture enrichment due to low reads. On the other hand, amplicon dropout and mispriming caused the loss of mutation G21987A and the erroneous addition of mutation T15521A respectively using amplicon enrichment. Overall, we found high sequence agreement regardless of method of enrichment, bioinformatic pipeline or the use of automation for library preparation in eight different SARS-CoV-2 variants. Automation and the use of a simple app for bioinformatic analysis can simplify the genotyping process, making it available for more diagnostic facilities and increasing global vigilance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain.
- Universidade de Vigo, Vigo, Spain.
- Microbiology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo, Spain.
- Dirección Xeral de Saúde Pública, Xunta de Galicia, Consellería de Sanidade, Santiago de Compostela, A Coruña, Spain.
ORCID-Profile: Carlos Daviña-Núñez, Sonia Pérez
Förderung
- European Centre for Disease Prevention and Control
- Axencia Galega de Innovación
- Servicio Gallego de Salud
Zitieren
APA
Daviña-Núñez, C., Pérez, S., Cabrera-Alvargonzález, J. J., Rincón-Quintero, A., Treinta-Álvarez, A., Godoy-Diz, M., Suárez-Luque, S., & Regueiro-García, B. (2024). Performance of amplicon and capture based next-generation sequencing approaches for the epidemiological surveillance of Omicron SARS-CoV-2 and other variants of concern. PLOS ONE. https://doi.org/10.1371/journal.pone.0289188
Vancouver
Daviña-Núñez C, Pérez S, Cabrera-Alvargonzález JJ, Rincón-Quintero A, Treinta-Álvarez A, Godoy-Diz M, et al. Performance of amplicon and capture based next-generation sequencing approaches for the epidemiological surveillance of Omicron SARS-CoV-2 and other variants of concern. PLOS ONE. 2024. doi:10.1371/journal.pone.0289188
BibTeX
@article{DaviaNez2024,
author = {Daviña-Núñez, Carlos and Pérez, Sonia and Cabrera-Alvargonzález, Jorge Julio and Rincón-Quintero, Anniris and Treinta-Álvarez, Ana and Godoy-Diz, Montse and Suárez-Luque, Silvia and Regueiro-García, Benito},
title = {Performance of amplicon and capture based next-generation sequencing approaches for the epidemiological surveillance of Omicron SARS-CoV-2 and other variants of concern},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0289188}
}
EUVIMED